Expertise in
21
conditions

Dr. Merrill K. Shum

Internal Medicine
16315 Whittier Blvd, 
Whittier, CA 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
22 Years of Experience
Expertise in
21
conditions
16315 Whittier Blvd, 
Whittier, CA 

Overview

Merrill Shum is an Internal Medicine provider in Whittier, California. Dr. Shum has been practicing medicine for over 22 years is highly rated in 21 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Colorectal Cancer, and Familial Colorectal Cancer.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Automade Guadalajara , Family Medicine , 2000 - 2004, 2004

Residency

Cooper Hospital-university Medical Center , Hematology & Oncology , 2002 - 2004

Specialties

Internal Medicine

Licenses

Internal Medicine in PA

Board Certifications

American Board Of Internal Medicine

Fellowships

Cancer Institute Of New Jersey At Cooper , Hematology & Oncology , 2004 - 2007

Hospital Affiliations

Pih Health Downey Hospital
Whittier Hospital Medical Center
Pih Health Hospital-Whittier

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Oncology Physicians Network Of California Pc
16315 Whittier Blvd, Whittier, CA 90603
Other Locations
Oncology Physicians Network Of California Pc
23600 Telo Ave, Torrance, CA 90505
Oncology Physicians Network Of California Pc
8135 Painter Ave, Whittier, CA 90602

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Enrollment Status: Recruiting
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin
Study Phase: Phase 2/Phase 3
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 09, 2026
Intervention Type: Drug
Study Drugs: Itacitinib, Osimertinib
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Brigatinib, Alectinib
Study Phase: Phase 3
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, AB680, Enzalutamide, Docetaxel
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Study Phase: Phase 1
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
A Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors
A Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: November 04, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer
A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer
Enrollment Status: Completed
Publish Date: August 20, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 13 Less Clinical Trials

3 Total Publications

Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia.
Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia.
Journal: Blood
Published: September 15, 2023
Similar Doctors
Expertise in
29
conditions
Dr. Sant P. Chawla
Internal Medicine
Expertise in
29
conditions
Dr. Sant P. Chawla
Internal Medicine

Cancer Center Of Southern California

2811 Wilshire Blvd, 
Santa Monica, CA 
 (29.0 miles away)
310-552-9999
Experience:
51+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sant Chawla is an Internal Medicine provider in Santa Monica, California. Dr. Chawla has been practicing medicine for over 51 years is highly rated in 29 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Myxoid Liposarcoma.

Expertise in
28
conditions
Dr. Ke-qin Hu
Internal Medicine
Expertise in
28
conditions
Dr. Ke-qin Hu
Internal Medicine

UCI Health

101 The City Dr S, 
Orange, CA 
 (11.8 miles away)
888-717-4463
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ke-qin Hu is an Internal Medicine provider in Orange, California. Dr. Hu is highly rated in 28 conditions, according to our data. His top areas of expertise are Hepatitis, Hepatitis B, Cirrhosis, and Hepatitis C.

Expertise in
11
conditions
Dr. James Waisman
Internal Medicine
Expertise in
11
conditions
Dr. James Waisman
Internal Medicine

City Of Hope's Helford Clinical Research Hospital

1500 Duarte Rd, 
Duarte, CA 
 (13.0 miles away)
626-359-8111
Languages Spoken:
English
See accepted insurances

James Waisman is an Internal Medicine provider in Duarte, California. Dr. Waisman is highly rated in 11 conditions, according to our data. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Breast Cancer in Men, and HER-2 Positive Breast Cancer.

Frequently Asked Questions about Dr. Merrill K. Shum

How do I make an appointment with Dr. Merrill K. Shum?

You can book an appointment with Dr. Merrill K. Shum by calling their office at 562-358-3360. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Merrill K. Shum a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Merrill K. Shum is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Merrill K. Shum specialize in?

While Dr. Merrill K. Shum is a Internal Medicine, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Merrill K. Shum participate in research or clinical trials?

Yes. Dr. Merrill K. Shum has published 3 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Merrill K. Shum's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Merrill K. Shum accept my insurance?

Dr. Merrill K. Shum accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 562-358-3360 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shum's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 124 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile